Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Herpes Simplex Virus Treatment Market

Herpes Simplex Virus Treatment Market Size

  • Report ID: GMI7466
  • Published Date: Nov 2023
  • Report Format: PDF

Herpes Simplex Virus Treatment Market Size

Herpes Simplex Virus Treatment Market size was around USD 2.6 billion in 2022 and is poised to expand at 4% CAGR from 2023 to 2032. Major growth factors for the market are increasing prevalence of herpes infection, rising research and development, growing government funding and awareness, globalization & increased travel, and increasing healthcare expenditure.

 

The rising prevalence of herpes infection is a significant contributor to the market. For instance, according to the Centers for Disease Control and Prevention (CDC), there were about 572,000 new genital herpes infections in the U.S. alone in 2021. As the prevalence of HSV infections increases, the number of individuals seeking diagnosis and treatment also rises, thus fostering the market expansion.
 

Herpes simplex virus (HSV) treatment refers to the medical interventions and therapeutic approaches aimed at managing and controlling infections caused by the herpes simplex virus. The treatment primarily focuses on alleviating symptoms, reducing the frequency and severity of outbreaks, and preventing the transmission of the virus to others. Antiviral drugs including acyclovir, valacyclovir, and famciclovir are commonly prescribed. They work by inhibiting the replication of the virus, reducing the severity of symptoms, and suppressing recurrent outbreaks.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Herpes simplex virus treatment industry was valued at USD 2.6 billion in 2022 and is projected to surpass USD 3.8 billion by 2032, driven by increasing prevalence of herpes infection, rising R&D, growing government funding, and increasing healthcare expenditure.

The HSV-1 segment held a market share of 83.2% in 2022 and is projected to witness substantial gains by 2032, driven by the increasing prevalence of HSV-1 infection among the population, along with the recurrent nature of oral herpes outbreaks.

North America herpes simplex virus treatment industry held a revenue share of 56.8% in 2022 & is anticipated to grow robustly through 2032 driven by significant burden of HSV infections and advanced healthcare infrastructure in the region.

GlaxoSmithKline plc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Limited, Amneal Pharmaceuticals LLCare some of the major industry contenders.

Herpes Simplex Virus Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2022
  • Companies covered: 10
  • Tables & Figures: 315
  • Countries covered: 19
  • Pages: 220
 Download Free Sample